Yildiz, Ramazan <br/><br/>
Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens.  [electronic resource] 

 -  Cancer investigation  Jan 2010 
 - 33-7 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1532-4192 
<br/><br/><label>Standard No.: </label>10.3109/07357900802562996  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bevacizumab<br/>Camptothecin--administration & dosage<br/>Chemotherapy, Adjuvant<br/>Colorectal Neoplasms--drug therapy<br/>Disease Progression<br/>Female<br/>Humans<br/>Irinotecan<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Retrospective Studies<br/>Time Factors<br/>Treatment Failure